Skip to main content
OpenTrials
Completed

NCT Number: NCT04565613

Protein Supplementation vs Standard Feeds in Underweight Critically Ill Children: A Dual-Centre Pilot RCT

This pilot trial is part of a long-term research program leading to a large trial to determine if a strategy of supplementing protein in a subset of critically ill children is superior to standard enteral nutrition care. The investigators hypothesize that protein supplementation to critically ill children with body mass index (BMI) z-score <0 reduces the length of stay in the paediatric intensive care unit (PICU) and hospital, as well as the duration of mechanical ventilation (MV).

Completed

Looking for future studies?

Notify Me

Key information

Age range

28 day–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National University Hospital

Singapore, 119228

About this study

Protein malnutrition is prevalent among critically ill children and associated with poor clinical outcomes. Current guidelines for provision of protein in daily management of critically ill children in pediatric intensive care units (PICUs) are based on limited and not high-quality evidence. The current protein supplementation approach, "one-size-fits-all" nutrition prescription, may not be appropriate for every critically ill child. Given the heterogeneity of the patients admitted to the PICU, a targeted approach based on individuals' needs represents a potential advancement in PICU care.

The central hypothesis is that protein supplementation in PICU care leads to improved clinical outcomes in subgroups of patients only. The investigators propose a dual-centre pilot randomized controlled trial in Singapore with two major aims:

  • To obtain key information for planning and conducting a large-scale multicentre study in Asia; and
  • to evaluate the benefit of protein supplementation to critically ill children with body mass index (BMI) z-scores on PICU <0

The main clinical outcome of interest is total number of days of hospital stay (from PICU admission to hospital discharge). Two protein supplementation regimes (≥ 1.5g/kg/day vs. standard care) will be randomly allocated to PICU patients with body mass index (BMI) z-scores <0. The investigators will determine the effect of protein supplementation on total length of hospital stay and other clinical outcomes, and assess the impact of protein supplementation on acquired functional impairment of PICU survivors 6 months after hospital discharge. In addition, the investigators will explore whether muscle ultrasound is a biomarker for protein balance in pediatric critical illness.

Upon completion of this study, the investigators will have strong preliminary data to plan, refine their study approach, and execute a future large multi-centre study across Asia. These data will ultimately guide protein provision and nutritional management of patients in PICU setting.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Between 28 days and 18 years of age
  • Have a BMI z-score < 0 on PICU admission
  • Requires respiratory support in the form of invasive or non-invasive mechanical ventilation (CPAP or BiPAP) within 24-48 hours of PICU admission, and the attending physician expects the child to require any respiratory support for at least 48 hours of PICU admission
  • Requires enteral nutrition support for feeding (e.g., oro-gastric, nasogastric, gastrostomy, naso-jejunal, oro-jejunal)
  • Have an expected PICU stay of > 48 hours

Exclusion criteria

  • Are not expected to survive this PICU admission because of palliative care (e.g., do-not-resuscitate status) or limited life support
  • Progressive neuromuscular disease (e.g., spinal muscular atrophy, Duchenne or other muscular dystrophy, multiple sclerosis, amyotrophic lateral sclerosis)
  • Medical conditions where increased or decreased protein intake is required, including acute kidney injury (stage 3 KDIGO criteria), chronic kidney disease (stage 4 and 5), inborn errors of metabolism, fulminant liver failure, severe burn injury
  • Contraindications to enteral nutrition (e.g., gut hemorrhage, post-gastrointestinal surgery etc.)
  • Diagnosed cow's milk protein allergy
  • Parenteral nutrition
  • Premature infants who are less than corrected gestational age of 44 weeks (gestational age + weeks after birth)
  • Were previously enrolled in this trial
  • Are currently enrolled in a potentially confounding trial
  • Diagnosis of anorexia nervosa and other eating disorders
  • On extra-corporeal membrane oxygenation (ECMO) support
  • Conditions that required significant fluid restriction (≤75% of maintenance fluid) (e.g., post cardiac surgery etc.)

Treatment and study plan

Enteral protein supplementation

Dietary Supplement

The participants in the study interventional group will receive protein supplementation to reach a final goal of 1.5 g/kg/day of protein on full feeds. This will be via 100% whey protein isolate (Nestle Beneprotein). Doses will be calculated on the patient's admission weight and rounded up to the nearest 1g. Doses will not be adjusted to account for weight changes in the PICU.

Protein supplementation will continue for a total of 7 days from the start of enrolment into the study or until PICU discharge, whichever is earlier. If the patient is able to take solid feeds during the study intervention period, the intervention will be stopped. However, if the device required for feeding is removed but the patient takes milk/liquid feeds fully, protein supplementation will continue.

Other names: Protein isolate (Nestle Beneprotein)

Primary outcomes

  1. Proportion of eligible patients approached for consent

    Time frame: Throughout study period, over 36 months

    Number of eligible patients who are approached for consent

  2. Proportion of participants receiving their first protein supplementation within 72 hours of enrolment

    Time frame: Throughout the study, over 24 months

    Number of patients who received protein supplementation within 72 hours of enrolment

  3. Participant accrual rate

    Time frame: Throughout the study, over 24 months

    Average monthly enrolment at each centre

  4. Protocol adherence

    Time frame: Throughout study period, over 24 months

    >80% of protein target administered according to the protocol in the intervention arm

Secondary outcomes

  1. PICU mortality

    Time frame: Throughout study period, over 36 months

    Death in PICU

  2. PICU length of stay

    Time frame: Throughout study period, over 36 months

    Duration of stay in the PICU

  3. Hospital length of stay

    Time frame: Throughout the study period, over 36 months

    Duration of stay in the hospital

  4. Adverse events

    Time frame: Throughout study period, over 36 months

    Development of adverse events such as feeding intolerance, diarrhoea, gastrointestinal bleeding

  5. Change in muscle size

    Time frame: During PICU stay, PICU discharge, hospital discharge and 6 months follow-up

    Longitudinal change in muscle size as assessed by ultrasound. Muscles for assessment include rectus femoris and diaphragm

  6. Anthropometry

    Time frame: During PICU stay, PICU discharge, hospital discharge and 6 months follow-up

    Change in anthropometric measurements

  7. Functional status

    Time frame: PICU admission, hospital discharge and 6 months follow-up

    Assessment of functional status via functional status scale (FSS). FSS scores ranged from 6 to 30. A higher score denotes worse outcome

Sponsors and collaborators

Lead sponsor

KK Women's and Children's Hospital

Other Gov

Collaborators

  • Duke-NUS Graduate Medical School
  • National Medical Research Council (NMRC), Singapore
  • Singapore Clinical Research Institute

Registry information

Official study title

Protein Supplementation Versus Standard Feeds in Underweight Critically Ill Children: A Dual-Centre Randomized Controlled Pilot Trial

Important dates

Study start
2021
Primary completion
2024
Study completion
2025
First posted
Sep 25, 2020
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.